1. Home
  2. LDP vs CTMX Comparison

LDP vs CTMX Comparison

Compare LDP & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Limited Duration Preferred and Income Fund Inc.

LDP

Cohen & Steers Limited Duration Preferred and Income Fund Inc.

N/A

Current Price

$20.38

Market Cap

615.9M

Sector

Finance

ML Signal

N/A

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

N/A

Current Price

$3.30

Market Cap

716.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LDP
CTMX
Founded
2012
2008
Country
United States
United States
Employees
N/A
69
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
615.9M
716.9M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
LDP
CTMX
Price
$20.38
$3.30
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$12.10
AVG Volume (30 Days)
61.9K
2.2M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
7.91%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.61
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$19.35
$1.90
52 Week High
$22.05
$8.21

Technical Indicators

Market Signals
Indicator
LDP
CTMX
Relative Strength Index (RSI) 35.41 47.01
Support Level $20.38 $3.01
Resistance Level $20.95 $3.55
Average True Range (ATR) 0.17 0.15
MACD -0.01 0.01
Stochastic Oscillator 7.14 31.17

Price Performance

Historical Comparison
LDP
CTMX

About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.

Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: